LU501034B1 - Production of nornicotine acyl-derivatives in a plant host - Google Patents
Production of nornicotine acyl-derivatives in a plant host Download PDFInfo
- Publication number
- LU501034B1 LU501034B1 LU501034A LU501034A LU501034B1 LU 501034 B1 LU501034 B1 LU 501034B1 LU 501034 A LU501034 A LU 501034A LU 501034 A LU501034 A LU 501034A LU 501034 B1 LU501034 B1 LU 501034B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- seq
- nucleotide sequence
- identity
- nornicotine
- fragment
- Prior art date
Links
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 title claims abstract description 74
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 71
- 108010029541 Laccase Proteins 0.000 claims abstract description 70
- 230000008569 process Effects 0.000 claims abstract description 59
- 239000002773 nucleotide Substances 0.000 claims description 92
- 125000003729 nucleotide group Chemical group 0.000 claims description 92
- 230000001747 exhibiting effect Effects 0.000 claims description 54
- 241000196324 Embryophyta Species 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- KEQBTQJDZSZAMQ-INIZCTEOSA-N 1-[(2s)-2-pyridin-3-ylpyrrolidin-1-yl]octan-1-one Chemical compound CCCCCCCC(=O)N1CCC[C@H]1C1=CC=CN=C1 KEQBTQJDZSZAMQ-INIZCTEOSA-N 0.000 claims description 17
- KEQBTQJDZSZAMQ-UHFFFAOYSA-N N-Octanoylnornicotine Natural products CCCCCCCC(=O)N1CCCC1C1=CC=CN=C1 KEQBTQJDZSZAMQ-UHFFFAOYSA-N 0.000 claims description 17
- 230000002255 enzymatic effect Effects 0.000 claims description 17
- 230000001131 transforming effect Effects 0.000 claims description 15
- NKXYWVGCISTJDE-UHFFFAOYSA-N 1-hexanoyl-2-pyridin-3-yl-pyrrolidine Natural products CCCCCC(=O)N1CCCC1C1=CC=CN=C1 NKXYWVGCISTJDE-UHFFFAOYSA-N 0.000 claims description 12
- 241000207746 Nicotiana benthamiana Species 0.000 claims description 12
- 241000589155 Agrobacterium tumefaciens Species 0.000 claims description 10
- 241000042002 Trametes sanguinea Species 0.000 claims description 10
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 claims description 10
- 240000004658 Medicago sativa Species 0.000 claims description 9
- 244000000003 plant pathogen Species 0.000 claims description 8
- 150000002989 phenols Chemical class 0.000 claims description 5
- JMFRWRFFLBVWSI-NSCUHMNNSA-N coniferol Chemical compound COC1=CC(\C=C\CO)=CC=C1O JMFRWRFFLBVWSI-NSCUHMNNSA-N 0.000 claims description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- 235000010624 Medicago sativa Nutrition 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 229940119526 coniferyl alcohol Drugs 0.000 claims description 2
- 235000001671 coumarin Nutrition 0.000 claims description 2
- 229960000956 coumarin Drugs 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 21
- 230000010474 transient expression Effects 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 39
- 241000208125 Nicotiana Species 0.000 description 19
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000002538 fungal effect Effects 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- -1 alkaloid compounds Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001290303 Nicotiana repanda Species 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000003886 aromatase inhibitor Substances 0.000 description 3
- 229940046844 aromatase inhibitors Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002363 herbicidal effect Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical compound COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000005162 X-ray Laue diffraction Methods 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 240000001436 Antirrhinum majus Species 0.000 description 1
- 102100029361 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000569835 Coriolopsis rigida Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000255908 Manduca sexta Species 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000392184 Nesophila Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000222393 Phanerochaete chrysosporium Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000044283 Toxicodendron succedaneum Species 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002540 product ion scan Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0061—Laccase (1.10.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention pertains to a process for preparing nornicotine acyl-derivatives in a plant host, through the transient expression of a plant laccase in said host. The present invention also pertains to nornicotine acyl-derivatives produced by a process according to the invention, and to compositions comprising said nornicotine acyl-derivatives.
Description
! LU501034
PRODUCTION OF NORNICOTINE ACYL-DERIVATIVES
IN A PLANT HOST
The present invention pertains to a process for preparing nornicotine acyl- derivatives in a plant host, through the transient expression of a laccase in said host. The present invention also pertains to nornicotine acyl-derivatives produced by a process according to the invention, and to compositions comprising said nornicotine acyl-derivatives.
The present invention therefore pertains to the field of recombinant production of alkaloid compounds of interest, compositions comprising said compounds as active agents and use of said alkaloid compounds.
Nornicotine acyl-derivatives (N-acyl nornicotines or NacNN) are 1000-fold more toxic to the insect Manduca sexta than nicotine and are thus powerful insecticides (Laue G. et al. “Fast track to the trichome: induction of N-acyl nornicotines precedes nicotine induction in Nicotiana repanda” Planta 210, 510-514, (2000)).
Additionally, nornicotine acyl-derivatives were shown to exert inhibitory effects on the germination of tobacco seeds, suggesting their use in the development of new herbicides (Matsuzaki T. et al. “Germination and
Growth Inhibition of Acylnornicotines from Section Repandae of the Genus
Nicotiana and Synthetic Acylnornicotines”. Agricultural and Biological
Chemistry 52, 1899-1903, (1988); JP63126875).
From a pharmacological point of view, acyl-derivatives of nornicotine, such as N-octanoylnornicotine, are breast cancer aromatase inhibitors. These compounds have been isolated in very little amounts from cigarette smoke (Osawa, Y. et al. "Aromatase inhibitors in cigarette smoke, tobacco leaves and other plants." J. Enzyme Inhib. 4, 187-200 (1990); Kadohama et al. "Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase".
Cancer Lett. 75, 175-182 (1993)).
2 LU501034
Aromatase inhibitors are also used in other applications, namely in the treatment of endometriosis (Wang, C. & Wilson, L. F. "Methods and
Compositions for the Treatment of Estrogen-Dependent Hyperproliferative
Uterine Disorders”. (2014); US2014080794A1), in cosmetic products influencing hair growth or treating cellulite (US25685499A,
US2020360734A1).
Due to their herbicide, insecticide and medical interest, there is a strong interest for developing a simple, fast and reliable process for producing nornicotine acyl-derivatives.
At present, the alkaloids nornicotine acyl-derivatives are found in low amount in some species only of wild tobacco, namely Nicotiana species repanda, stocktonii and nesophila. These compounds have also been found as minor components of cigarette smoke.
The biosynthesis of these compounds takes place in the trichomes, is induced upon elicitation with methyl jasmonate or wounding and this induction precedes that of their precursor nornicotine (Laue et a/., 2000).
Outchkourov et al. (Outchkourov et al. « Control of anthocyanin and non- flavonoid compounds by anthocyanin-regulating MYB and bHLH transcription factors in Nicotiana benthamiana leaves.” Front. Plant Sci. 5, (2014)) discloses the production of N-hexanoylnornicotine and N-octanoylnornicotine upon agroinfiltration of N. benthamiana with two genes coding for the transcription factors ROS1 and DEL from snapdragon. ROS1 and DEL form a pair of transcription factor which specifically induce anthocyanin accumulation when expressed in tomato fruit.
The inventors have now developed a process for producing increased levels of nornicotine acyl-derivatives in a plant host cells by using the transient expression of a protein exhibiting a laccase enzymatic activity, in particular a laccase. In a particular embodiment, a process according to the invention for producing nornicotine acyl-derivatives involves the transient expression in a tobacco leaves of a plant laccase. In another particular embodiment, a process according to the invention involves the transient expression in tobacco leaves of a fungal laccase.
3 LU501034
The present invention is based on the unexpected finding that tobacco leaves, transiently transformed with only one nucleotide sequence coding for a laccase, are able to produce at least one nornicotine acyl-derivative in higher quantity than when compared to the level of the same nornicotine acyl-derivative in control tobacco leaves.
The inventors defined a process comprising the production of at least one nornicotine acyl-derivative, said process comprising the steps of: i) transforming a plant host cell with a vector comprising a nucleotide sequence coding a protein exhibiting a laccase enzymatic activity, ii) cultivating said transformed host cell in appropriate culture conditions and iii) isolating at least one nornicotine acyl-derivative from said cultivated transformed host cells.
The nature and quantity of products obtained by a process according to the present invention are unexpected, as no prior data points to the role of laccases within the nornicotine acyl-derivative synthesis pathway.
A process according to the invention presents several advantages over processes disclosed in the prior art, as it involves the transient expression of only one gene and allows for the production of nornicotine acyl-derivatives of at least 1.5 fold, without requiring the separation of compounds from cigarette smoke nor eliciting, nor wounding, wild tobacco species. Indeed, in as short as a few days, for example 5-7 days, a high induction of N- acylnornicotine derivatives is obtained. Therefore, a process according to the invention is a fast and easy way for producing different and useful nornicotine acyl-derivatives in tobacco. A process according to the invention is furthermore safer and more ecological than processes of the prior art, and is less complicated, less labor-intensive, more user friendly than currently available processes.
In a first aspect, the present invention provides a process for the production of at least one nornicotine acyl-derivative, said process comprising the steps of:
4 LU501034 ° transforming a plant host cell with a vector comprising a nucleotide sequence coding a protein exhibiting a laccase enzymatic activity, ° cultivating said transformed host cell, and ° isolating at least one nornicotine acyl-derivative from said cultivated transformed host cell.
In a second aspect, the present invention provides a transformed plant host cell for the production of at least one nornicotine acyl-derivative. In a third aspect, the present invention provides the use of a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, for the production of at least one nornicotine acyl-derivative in a plant host cell. In a fourth aspect, the present invention provides a composition comprising at least one nornicotine acyl-derivative obtained by a process according to the invention, said composition being preferably chosen among a pharmaceutical composition, a cosmetic composition, a herbicidal composition and an insecticidal composition.
Characteristics, advantages and uses of the subject-matter of the present invention are more detailed hereunder, in an illustrated and non-limiting way. When present, the disclosure of the ranges expressed as “from ... to ...” means that the limits are included in said ranges.
Figure 1(a) represents a chromatogram of LC-MS analysis of
MsLaccase103204 after transient expression in N. benthamiana; leaves agro-infiltrated with the suppressor of silencing p19 were used as a negative control. The chromatogram is presented as selected ion plots of the m/z 275.2113 [M+H] ion.
Figure 1(b) represents the mass spectra of N-octanoylnornicotine.
In a first aspect, the present invention relates to a process for the production of at least one nornicotine acyl-derivative, said process comprising the steps of:
D) transforming a plant host cell with a vector comprising a 5 nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity,
ID) cultivating said transformed host cell obtained at step i), and iii) isolating at least one nornicotine acyl-derivative from said cultivated transformed host cell.
By "comprising" is meant that the element is present but that other elements may also be present. In the case of an amino acid sequence, the subject sequence may in particular further comprise additional amino acids, on the N-terminal or C-terminal side of said sequence, these additional amino acids making it possible in particular to facilitate the characterization and / or purification of the protein of interest. In the case of a nucleotide sequence, the subject sequence may in particular further comprise additional nucleotides, on the 3’ or 5’ side of said sequence.
By "consisting of" is meant that no element other than those mentioned is present. This limitation, however, includes possible post-translational modifications of the protein of interest.
By “cultivating said transformed host cell” it is intended providing to said transformed host cell an environment appropriate for its development, according to conditions and methods well known by a person skilled in the art. In a particular embodiment, said host cell is cultivated for 4, 5, 5, 6, 7 or 8 days. By “isolating” it is intended separating, or retrieving said at least one nornicotine acyl-derivative using any appropriate method well known by a person skilled in the art.
For the purpose of the invention, a “laccase” is a multicopper benzenediol oxygen oxidoreductase (EC 1.10.3.2) found in plants, fungi and bacteria.
Laccases oxidize a variety of phenolic substrates through one-electron oxidation, coupled to a four-electron reduction of molecular oxygen to water.
Laccases are classified for biochemical applications as low-, medium- and high-redox potential enzymes. This classification is based on the equilibrium
6 LU501034 potentiometric titrations of the redox potential at the T1Cu site, where the substrate is oxidized. Said redox potential ranges from 0.43 to 0.79 V in reference to the normal hydrogen electrode (Mateljak et al “Increasing redox potential, redox mediator activity and stability in a fungal laccase by computer-guided mutagenesis and directed evolution”, ACS Catalysis, 2019, 9, 4561-72). A high redox potential laccase is characterized by a redox potential comprised between 0.7 and 0.8 V, a medium redox potential laccase is characterized by a redox potential comprised between 0,5 and 0,6
V, a low redox potential laccase is characterized by a redox potential comprised between 0.4 and 0.5 V.
As a reference, by “laccase enzymatic activity” it is intended an enzymatic activity wherein a reference laccase substrate, for example 2,6 dimethoxy- phenol, is oxidized in defined experimental conditions known in the prior art (Mateljak et al., “Increasing redox potential, redox mediator activity, and stability in a fungal laccase by computer-guided mutagenesis and directed evolution”, ACS Catalysis, 9, 4561-4572).
In more specific embodiments, a process according to the invention comprises the step of transforming a plant host cell with a vector comprising a nucleotide sequence coding for a high redox potential laccase, a nucleotide sequence coding for a medium redox potential laccase or a nucleotide sequence coding for a low redox potential laccase.
Laccases from plant, fungi and bacteria are suitable for a process according to the invention. In more specific embodiments, a process according to the invention comprises the use of a vector comprising a nucleotide sequence coding for a plant laccase, a fungal laccase, or a bacteria laccase.
Among high-redox potential laccases, one can cite fungal laccases such as, for example laccases from Pycnoporus sanguineus, Coriolopsis rigida,
Ganoderma lucidum, Phanerochaete chrysosporium, Trametes versicolor,
Polyporus spp. and other Basidiomycetes.
More specifically, a process according to the invention uses a vector comprising a nucleotide sequence coding for a fungal laccase, said fungi being chosen among Basidiomycetes. Even more specifically, a process
7 LU501034 according to the invention makes use of a vector comprising a nucleotide sequence coding for a P. sanguineus laccase.
Among low-redox potential laccases, one can cite plant laccases such as, for example MsLaccase103204 from Medicago sativa and laccase from the lacquer tree Rhus vernicifera.
The laccase Lac103204 extracted from M. sativa, also referred to as alfalfa, is coded by the nucleotide sequence SEQ ID N°1. M. sativa laccase
Lac103204 has the amino acid sequence SEQ ID N°7
In a particular embodiment, a process of the present invention comprises the steps of: ° transforming a plant host cell with a vector comprising a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, said nucleotide sequence being chosen among: v SEQ ID N°1, v a nucleotide sequence exhibiting at least 80% identity with SEQ
ID N°1, v a fragment of at least 150 nucleotides of SEQ ID N°1 and v a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, e cultivating said transformed host cell, and ° isolating at least one nornicotine acyl-derivative from said cultivated transformed host cell.
By “exhibiting at least 80% identity” is meant that said sequence exhibits at least 80% identity after optimal overall alignment with another sequence, that is to say by global alignment between two sequences giving the highest percentage identity between them. The optimal global alignment of two sequences can in particular be carried out according to the Needleman-
Wunsch algorithm, well known to those skilled in the art (Needleman &
Wunsch, "A general method applicable to the search for similarities in the amino acid sequences of two proteins”, J. Mol. Biol., 48 (3): 443-53).
By “a sequence exhibiting at least 80% identity”, it is intended a sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
8 LU501034 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the cited sequence. v By “a fragment of at least 150 nucleotides”, it is intended a nucleic acid sequence comprising at least 150, 200, 250, 280, 290 or 300 nucleotides of said of SEQ ID N°1 or SEQ ID N°4 sequence.
In another particular embodiment, the present invention relates to a process for the production of at least one nornicotine acyl-derivative, said process comprising the steps of transforming a plant host cell with a vector comprising a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, wherein said protein is chosen among: v M. sativa laccase Lac103204 having the amino acid sequence
SEQ ID N°7, v a protein having an amino acid sequence exhibiting at least 80% identity with SEQ ID N°7, v a protein having an amino acid sequence identical to a fragment of at least 50 amino acids of SEQ ID N°7 and v a protein having an amino acid sequence of at least 50 amino acids, said sequence exhibiting at least 80% of identity with SEQ ID
N°7.
The laccase extracted from P. sanguineus BRFM66 is encoded by the nucleotide sequence SEQ ID N°4, its amino acid sequence is SEQ ID N°8, and is published as COWKP8-1 in Uniprot Database. Trametes sanguinea and
P. sanguineus are different names designating the same organism.
In another particular embodiment, a process according to the invention comprises the step of transforming a plant host cell with a vector comprising a nucleotide sequence chosen among: v SEQID N°4, v a nucleotide sequence exhibiting at least 80% identity with SEQ
ID N°4, v a fragment of at least 150 nucleotides of SEQ ID N°4 and v a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4,
9 LU501034 for the production of at least one nornicotine acyl-derivative in a plant host cell.
In another particular embodiment, the present invention relates to a process for the production of at least one nornicotine acyl-derivative, said process comprising the steps of transforming a plant host cell with a vector comprising a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, wherein said protein is chosen among: v P. sanguineus laccase having the amino acid sequence SEQ ID
N°8, v a protein having an amino acid sequence exhibiting at least 80% identity with SEQ ID N°8, v a protein having an amino acid sequence identical to a fragment of at least 50 amino acids of SEQ ID N°8 and v a protein having an amino acid sequence of at least 50 amino acids, said sequence exhibiting at least 80% of identity with SEQ ID
N°8.
In a particular embodiment of this first aspect, the present invention relates to a process for producing at least one nornicotine acyl-derivative, said nornicotine acyl-derivative being preferably chosen among the following: N- hexanoylnornicotine, N-octanoylnornicotine, N-nonanoylnornicotine, and a combination thereof. In a particular embodiment, the present invention relates to a process for producing at least one nornicotine non hydroxylated acyl-derivative.
By “nornicotine” it is intended a de-methylated derivative of nicotine, represented as a compound of formula I. = H
NM
(Formula I)
By “nornicotine acyl-derivative” it is intended a nornicotine compound which is bound to an acyl group. Nornicotine acyl-derivatives comprise
10 LU501034 hydroxylated and nonhydroxylated nornicotine acyl-derivatives, as shown for example in Figure 1 of Laue et a/.
In the invention, non-hydroxylated nornicotine acyl-derivatives nornicotine acyl-derivatives are preferably represented by Formula II, wherein for example n=9 for N-dodecanoic acid nornicotine, were found to be induced after a transient expression of a plant or a fungal laccase.
Ze
N
> g— 0
I lL (Formula II)
In a particular embodiment, a process according to the invention provides at least one non-hydroxylated nornicotine acyl derivative, said non- hydroxylated nornicotine acyl derivative being preferably chosen among: N- hexanoylnornicotine, N-octanoylnornicotine and N-nonanoylnornicotine.
By “N-hexanoylnornicotine” it is intended N-hexanoylnornicotine (CisH220N2) as represented by Formula III and mentioned in Outchkourov et a/., 2014. =
L
>
NM g— 0 lL, (Formula III)
By "N-octanoylnornicotine” it is intended N-octanoylnornicotine (Ci7H260N2) as represented by formula IV and mentioned in Outchkourov et al., 2014.
11 LU501034 = 8 =
N e— 0
L,
Le (Formula IV)
By "N-nonanoylnornicotine” it is intended N-nonanoylnornicotine (C:sH2sON2) as represented by formula V. =
Ç
=
N go
Le (Formula V)
IN a more particular embodiment, a process according to the present invention comprises a step of transforming a plant host cell with a vector comprising a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, wherein said vector is itself integrated into a plant pathogen. In a particular embodiment, said plant pathogen is Agrobacterium tumefasciens, or any plant pathogen known by a person skilled in the art to be able for this purpose. Depending on said plant pathogen used in a process of the invention, a person skilled in the art will select the appropriate vector, in particular a binary vector adapted to transform said plant pathogen.
12 LU501034
Production of a suitable gene product may be achieved using recombinant techniques. For example, a suitable vector may be inserted into a host cell and expressed in that cell.
In a process according to the invention, the nucleotide sequence is functionally associated with the necessary means for the expression of the recombinant protein in said host cell. Said elements include a nucleotide sequence enabling the regulation of the protein expression, such as a promoter sequence, a transcription terminator, an origin of replication, and optionally a selection marker.
Such a nucleic acid may be in the form of a vector. As used herein, the term "vector" refers to a nucleic acid molecule capable of replicating into the host cell and of transporting another nucleic acid by means of insertion into e.g. a multiple cloning site. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors).
However, the invention is intended to include such other forms of expression vectors, such as binary vectors and viral vectors including, but not limited to, replication defective retroviruses, adenoviruses, lentiviruses and adeno- associated viruses (AAV), which serve equivalent functions.
Ex vivo introduction may be performed by any standard method well known by one skilled in the art, including, but not limited to, transfection, electroporation, microinjection, transduction, cell fusion, polyethylene glycol (PEG), diethylaminoethyl (DEAE) dextran, calcium phosphate precipitation, or use of a gene gun.
13 LU501034
The polynucleotide coding for a laccase can also be introduced ex vivo or in vivo by lipofection. In certain embodiments, the use of liposomes and/or nanoparticles is contemplated for the introduction of the donor nucleic acid targeting system into host cells. Nanocapsules can generally entrap compounds in a stable and reproducible way. Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles, also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 A, containing an aqueous solution in the core.
In a more particular embodiment of this first aspect, the present invention relates to a process for the production of at least one nornicotine acyl- derivative, said process comprising the step of transforming a Nicotiana benthamiana host cell with a vector comprising a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, wherein said vector is itself integrated in the plant pathogen vector Agrobacterium tumefaciens, and wherein said transforming step is a transient transformation.
More particularly, the present invention relates to a process for the production of at least one nornicotine acyl-derivative, wherein said transforming step is performed in the presence of a phenolic compound. In a particular embodiment, for the transformation step of a process according to the present invention, said phenolic compound is chosen among: acetosyringone (abbreviated as "acs”), coniferyl alcohol, cinnamic acid, coumarin and vanillin. In a process according to the invention, a preferred phenolic compound for transformation is acs.
In a second aspect, the present invention relates to a transformed plant host cell comprising a vector comprising a nucleotide sequence chosen among: v SEQ ID N°1, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, a fragment of at least 150 nucleotides of
SEQ ID N°1, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1,
14 LU501034 v SEQ ID N°4, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, a fragment of at least 150 nucleotides of
SEQ ID N°4, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4.
In a particular embodiment of this second aspect, the present invention relates to a transformed N. benthamiana host cell comprising A. tumefaciens, wherein said A. tumefaciens comprises a nucleotide sequence chosen among: vr SEQ ID N°1, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, a fragment of at least 150 nucleotides of
SEQ ID N°1, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, v SEQ ID N°4, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, a fragment of at least 150 nucleotides of
SEQ ID N°4, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4.
In a third aspect, the present invention relates to the use of a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity for the production of at least one nornicotine acyl-derivative in a plant host cell.
More particularly, the present invention relates to the use of a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity and chosen among:
SEQ ID N°1, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, a fragment of at least 150 nucleotides of
SEQ ID N°1, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, v SEQ ID N°4, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, a fragment of at least 150 nucleotides of
SEQ ID N°4, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, for the production of at least one nornicotine acyl-derivative in a plant host cell.
15 LU501034
In another aspect, the present invention relates to use of an amino acid sequence chosen among: v SEQ ID N°7, an amino acid sequence exhibiting at least 80% identity with SEQ ID N°7, a fragment of at least 50 amino acids of
SEQ ID N°7, a fragment of at least 50 amino acids of an amino acid sequence exhibiting at least 80% identity with SEQ ID N°7, v SEQ ID N°8, an amino acid sequence exhibiting at least 80% identity with SEQ ID N°8, a fragment of at least 50 amino acids of
SEQ ID N°8, a fragment of at least 50 amino acids of an amino acid sequence exhibiting at least 80% identity with SEQ ID N°8, for the production of at least one nornicotine acyl-derivative in a plant host cell.
In a fourth aspect, the present invention pertains to a composition comprising at least one nornicotine acyl-derivative obtained by a process according to the invention. More particularly, said composition comprises at least one of the following nornicotine acyl-derivative: N-hexanoylnornicotine,
N-octanoylnornicotine and N-nonanoylnornicotine.
In a particular embodiment of this fourth aspect, the present invention pertains to a composition comprising at least one nornicotine acyl-derivative obtained by a process according to the invention, wherein said composition is chosen among a pharmaceutical composition, a cosmetic composition, an herbicidal composition and an insecticidal composition.
In a more particular embodiment of this fourth aspect, the present invention pertains to a pharmaceutical composition comprising, as an active ingredient, at least one nornicotine acyl-derivative obtained by a process according to the invention, said at least one nornicotine acyl-derivative being chosen among: N-hexanoylnornicotine, N-octanoylnornicotine and N- nonanoylnornicotine, or a combination thereof.
The term “active agent” refers to a chemical compound or a composition that exhibits a desirable effect in the biological context, either when administered to a subject of evaluated in vitro. The term includes pharmaceutically acceptable derivatives of those active agents. A pharmaceutical composition according to the present invention comprises a
16 LU501034 therapeutically effective amount of at least one nornicotine acyl-derivative.
A "therapeutically effective amount” is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject.
For example, a "therapeutically effective amount” to a mammal is such an amount which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder.
More particularly, the present invention relates to a pharmaceutical composition comprising, as an active ingredient, at least N- hexanoylnornicotine N-octanoylnornicotine and N-nonanoylnornicotine, or a combination thereof, obtained by a process according to the invention.
The pharmaceutical composition of the present invention may consist essentially of the active ingredient and at least one physiologically compatible carrier, excipient or diluent. Said carrier, excipient or diluent is a conventional pharmaceutically acceptable carrier, excipient or diluent, suitable for the desired mode of administration of said pharmaceutical composition.
Examples of dosage forms used for administration of the pharmaceutical composition of the present invention include tablets, granules, powders, capsules, syrups, suspensions, injections, and eye drops. Agents, ointments, patches and the like. These dosage forms can be manufactured using a technique widely used as a usual preparation method, for example, tablets, capsules, oral preparations such as granules, lactose, starch, crystalline cellulose as needed, vegetable oils and other bulking agents, magnesium stearate, lubricants such as talc, binders such as hydroxypropylcellulose and polyvinylpyrrolidone, disintegrators such as calcium carboxymethylcellulose, coating agents such as hydroxypropylcellulose, macrogol and silicone resin
The active ingredient can be formulated using a gelatin coating agent.
For example, a pharmaceutical composition of the invention comprises 0.1 mg, 10 mg, 20 mg, 50 mg, or 100 mg or the like as a dosage unit amount of the active ingredient.
17 LU501034
In a particular embodiment, the present invention relates to a pharmaceutical composition comprising at least N-hexanoylnornicotine, N- octanoylnornicotine, N-nonanoylnornicotine, or a combination thereof.
In a particular embodiment, the present invention relates to a pharmaceutical composition comprising, as an active ingredient, N- octanoylnornicotine obtained by a process according to the invention, for its use in the prevention or the treatment of breast cancer or of endometriosis.
In another particular embodiment, the present invention relates to a cosmetic composition comprising N-octanoylnornicotine for its use for influencing hair growth or treating cellulite.
The present invention also provides a method of prevention or treatment of a pathology chosen among breast cancer and endometriosis, said method comprising the administration, to a patient in need thereof, of pharmaceutical composition comprising N-octanoylnornicotine obtained by a process according to the invention.
For a method according to the present invention, said administration is for example chosen among oral, parenteral, intravenous, intramuscular, transdermal, eye drops, intra-auricular or subcutaneous. These administration methods and dosage forms are to be selected according to the patient's condition, age and treatment. The present invention is particularly for mammalian, preferably humans.
Example 1: Production of nornicotine acyl-derivatives in tobacco leaves using laccase from M. sativa
Materials and Methods e Cloning of MsaLac103204 from alfalfa and transient expression in tobacco leaves
The construct for MsaLac103204 agroinfiltration in tobacco (Nicotiana benthamiana) was prepared by PCR amplification of Lac103204 cDNA sequence using Q5 DNA polymerase (NEB) with primers MsaLac103204 Fwd
18 LU501034 (B’-CACCATGACACGATTTATGTITITCTCTAGCATGG-3') (SEQ ID N°2) and
MsaLac103204 Rev (5'-ACACTTAGGAAGATTAGCTGGTGGAGGAGG-3’) (SEQ
ID N°3) to generate an amplification product without stop codon. The PCR product was PCR purified after verification of the right size with gel electrophoresis and cloned into the Gateway pENTR/D-TOPO vector using the directional TOPO cloning kit (Invitrogen) following the manufacturer's instructions. The open reading frame of MsaLac103204 was thereafter recombined using the Gateway LR Clonase II Enzyme mix (Invitrogen) into the destination vector pEarleyGate103 to create a C-terminal fusion to GFP (Earley et al. “Gateway compatible vectors for plant functional genomics and proteomics”, Plant. J. Feb(45):616-29, 2006). All constructs were checked by sequencing on an Applied Biosystems 3500 Genetic Analyser using the
BigDye Terminator v3.1 Cycle Sequencing and the BigDye XTerminator
Purification kits, according to the manufacturer’s instructions.
The verified construct was transformed in Agrobacterium tumefaciens
GV3101-pMP90 using heat shock. The two A. tumefaciens GV3101-pMP90 strains (transformed with p103::MsaLac103204 and the silencing suppressor pBIN61-p19, respectively) were grown in 50 ml of Luria-Bertani (LB) medium supplemented with gentamycin (30 mg 1°), rifampicin (10 mg F*), kanamycin (50 mg I) at 30°C. Bacteria were sedimented by centrifugation at 3000g for 15 min at room temperature and resuspended in infiltration solution (10 mM MES pH 5.6 and 10 mM MgClz2) supplemented with 150 ug ml! acetosyringone. Bacterial suspensions were adjusted to a final ODeoo of 1.0 for the silencing suppressor and 0.8 for p103::MsaLac10304. Cells were left in this medium in the dark for 2-3 h.
Tobacco plants (Nicotiana benthamiana) were grown in phytotrons under a 16h light at 25°C/8h dark at 20°C regime. Agroinfiltration (mixtures containing the same volume of strains transformed with the suppressor of silencing and MsaLac103204 were injected and, as a control, only the bacteria transformed with the suppressor were infiltrated) was carried out on plants showing 4 fully-expanded leaves (ca. 4 weeks-old plants) by injecting agrobacteria in the abaxial sides. After agroinfiltration, tobacco
19 LU501034 plants were put back in the growth chambers for 5 days. After 5 days, the extraction of metabolites was carried out. e Extraction of metabolites from tobacco leaves
Leaf tissue sample (100 mg) from 3 pooled leaves was homogenized in liquid nitrogen and extracted with 1 ml of methanol:water (4:1, v/v). This mixture was then homogenized using a vortex for 30 s, sonicated for 10 min and shaken for 4 h at room temperature. After centrifugation at 10000 g for 15 min, the supernatant was collected and evaporated to dryness using a centrifugal vacuum evaporator. Dried N. benthamiana extracts were resuspended in 600 ul of ethanol:water (1:1, v/v) and filtered through a syringe filter (0.2 um, PTFE Millex-LG (Merck KGaA, Darmstadt, Germany). e UPLC-TripleTOF Analysis
Extracts were analyzed with a Waters Acquity UPLC system (Milford, MA) hyphenated to a high resolution time of flight mass spectrometer (TripleTOF 6600+, AB Sciex, Concord, Ontario, Canada). The separation of 5 ul aliquot was performed on a reverse-phase Acquity UPLC BEH C18 column (2.1 x 100 mm, 1.7 um particle size, Waters). In positive mode, the eluents were 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). In negative mode, the solvents were (A) H20 with 2.5 mM (v/w) ammonium acetate and (B) acetonitrile. The gradient was as follows: 0 min, 1% B; 4 min, 1% B; 16 min, 5% B; 35 min, 40% B; 45 min, 100% B; 50 min, 100%
B; 53 min, 1% B; 60 min, 1% B. The flow rate was of 0.5 ml min and the column temperature was 50°C. Analytes were positively ionized with electrospray ionization (ESI) source using the following parameter values for the positive and negative mode: source temperature, 650°C; ion spray voltage of 4.5 and - 4.5 kV, respectively, curtain gas (nitrogen) of 30, nebulizer gas (air) of 55, and turbine gas (air) of 50. Precursor charge state selection was set at 1. For information dependent acquisition (IDA in high sensitivity mode), survey scans were acquired in 175 ms and the 10 most abundant product ion scans were collected if exceeding a threshold of 100 counts per sec. The total cycle time was fixed at 2.25 s. Four time bins were summed for each scan at a pulser frequency value of 16.4 kHz. A sweeping collision energy setting of 15 eV in positive and - 15 eV in negative mode
20 LU501034 and was applied to all precursor ions for collision-induced dissociation. The declustering potential was set at 60 eV and - 60 eV in positive and negative mode, respectively. Dynamic exclusion was set for 8 s after 2 occurrences, and then the precursor is refreshed off of the exclusion list. For MS1, full
HR-MS spectra between 100 and 1300 mass-to-charge ratio (m/z) were recorded. MS2 scans were recorded between 25 and 1300 m/z. ° Data Processing
Data were first processed with MS Data Converter (Beta v1.3, AB SCIEX,
Concord, Ontario, Canada). The software converts the raw data (*.wiff) into peak lists (*.mzML). The Proteowizard software (v3.0, Chambers et al., 2012) was then used to transform the files into *.mzXML. The *.mzXML files (containing MS1 data only) were processed using XCMS online (https://xcmsonline.scripps.edu/) for feature detection, alignment, and statistical analysis to highlight metabolites of interest. The software
PeakView (v 1.2 0.3, AB SCIEX, Concord, Ontario, Canada) combined with the Metlin and PubChem database (https://pubchem.ncbi.nlm.nih.gov) as well as literature data were used for structure elucidation.
Results
A metabolic profiling was performed using UPLC-TripleTOF in both positive and negative mode. Figure 1 represents a chromatogram of LC-MS analysis of MsLaccase103204 after transient expression in N. benthamiana.
In positive mode, 12 metabolite features were identified that significantly changed after agroinfiltration with MsLaccase103204 (with fold change > 1.5). After removal of isotopes, fragment ions, and unclear mass spectra, 4 metabolites matched the PubChem and METLIN database (Table 1).
21 LU501034
Average area of the peak in AIC Average area of the peak in
XIC
Putative 103204 | 103204 P19 P18 FC FC identity, +acs -acs +acs -acs 103204 103204 molecular formula and +acs/p19+acs -acs/pis- refsrence acs
Nornicotine 2.36 10° | 1.80 40° | 1.39 10° | 8.95 10° 1.7 2.0
C9H12N2
METLIN
Athexanoyi 325 10° | 1.70 40° | 1.77 10° | 6.85 10° 18 25 nornicotine
C15HZ2N20
Dutchkourow, 2014
A-octanoyl 165107 | 9.75 10° | 9,74 10° | 4.95 105 1.7 2.0 nornicotine
C17H26N20
Outchkourov, 2014
A-nonanoyl- 190 10% | 157 40° | 943105 | 5.71 10° 2.0 27 nornicotine
C1BH28N20
Table 1
Increases in the fold change (FC) of the average peak area in the extracted ion chromatographs (XIC) of nornicotine and acylated nornicotine derivatives were observed when comparing leaves expressing the alfalfa laccase vs the p19 silencing suppressor (Table 1). These conjugated molecules are strong defensive compounds against insect herbivores. The largest metabolite increase was observed for N-octanoyl-nornicotine and N- hexanoylnornicotine (Table 1).
It should be noted that the addition of the compound acetosyringone (acs), known to be a mediator of laccases and routinely used in agro-infiltration
22 LU501034 assays to increase the virulence of the bacteria used for agro-infiltration, increased the average area of the peaks identified as compared to the samples obtained in the absence of acetosyringone.
Acylated nornicotine derivatives were not detected in the non-infiltrated (wild-type) leaves.
The inventors repeated this experiment and obtained an increase in the fold change of at least 1.5, in particular an increase with fold change of 4 or 5, when compared to appropriate controls, such as controls indicated in Table 1.
Example 2: Production of nornicotine acyl-derivatives in tobacco leaves using laccase from Pycnoporus sanguineus
Materials and Methods e Transient expression of Pycnoporus sanguineus laccase in tobacco leaves
The construct for Pycnoporus sanguineus laccase agroinfiltration in tobacco (N. benthamiana) was prepared by PCR amplification of FJ858749 cDNA sequence using Q5 DNA polymerase (NEB) with primers Psanguineus laccase
Fwd (5'-CACCATGTCGAGGTTCCAGTCTCTCCTCTC-3’) (SEQ ID N°5) and
Psanguineus laccase Rev (5'-GAGATCGCTAGGGTCAAGCGCGTCGTAGAT-3") (SEQ ID N°6) to generate an amplification product without stop codon.
The PCR product was then treated according to methods described in
Example 1 and transformed in Agrobacterium tumefaciens GV3101-pMP90 using heat shock. The two A. tumefaciens GV3101-pMP90 strains (transformed with p103:: Psanguineus laccase and the silencing suppressor pBIN61-p19, respectively) were grown and infiltrated as described in example 1.
Extraction of metabolites from tobacco leaves, UPLC-TripleTOF analysis and data processing were performed as described in example 1.
Results
A metabolic profiling was performed using UPLC-TripleTOF in positive mode.
23 LU501034
The compounds nornicotine, N-hexanoylnornicotine, N-octanoynornicotine and N-nonanoylnornicotine were specifically looked at (Table 2).
Putative identity, Average of intensity of the lon at Average area of the peak in XIC motecutar forma XiC peak apex {cps} and reference
Fang pis+acs Psangiac+acs pis+acs Fi. Psang lec+ace EE a we lac+acs/p!S5+acs
Nornicotine
CSHI2NZ 264 15° 2.27 40% 2.45 10° 2,81 105 8.7
Metine
A-hexanoyl nornicotne < ; 5 ä 23119 25384 S87 10° A42 10° T7
CISHZZNZ0
Gutchkogroy, 2014
A-octanoyt nornicoiine à = = = 1,30 19° 1,35 10° 3.41 16° 3.56 10° 25
CITHZENZO
Cutehkowroy, 2014
M-nonanoyi- nornicotne 8.04 104 1,52 10° 2.09 10° 4.00 19° 5.2
CISHZBH20
Table 2
Increases in the fold change (FC) of the average peak area in the extracted ion chromatographs (XIC) of nornicotine and acylated nornicotine derivatives were observed when comparing leaves expressing the laccase vs the p19 silencing suppressor (Table 2). The highest FC was observed for N- octanoylnornicotine.
Claims (13)
1. Process for the production of at least one nornicotine acyl-derivative, said process comprising the steps of: D) transforming a plant host cell with a vector comprising a nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity, ID) cultivating said transformed host cell obtained at step i), and iii) isolating at least one nornicotine acyl-derivative from said cultivated transformed host cell.
2. Process according to claim 1, wherein said protein exhibiting a laccase enzymatic activity is chosen in the group consisting of: high redox potential laccases, medium redox potential laccases and low redox potential laccases.
3. Process according to claim 1 or 2, wherein said nucleotide sequence is chosen among: / SEQ ID N°1, v a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, v a fragment of at least 150 nucleotides of SEQ ID N°1 and ¥ a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1.
4. Process according to claim 3, wherein said protein is Medicago sativa laccase Lac103204 having the amino acid sequence SEQ ID N°7.
5. Process according to claim 1 or 2, wherein said nucleotide sequence is chosen among: / SEQ ID N°4, ‘ a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, ‘ a fragment of at least 150 nucleotides of SEQ ID N°4 and
25 LU501034 ‘ a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4.
6. Process according to claim 5, wherein said protein is Pycnoporus sanguineus BRFM66 laccase having the amino acid sequence SEQ ID
N°8.
7. Process according to any one of claims 1 to 6, wherein said at least one nornicotine acyl-derivative is a nornicotine acyl-derivative chosen among: N-hexanoylnornicotine, N-octanoylnornicotine and N- nonanoylnornicotine.
8. Process according to any one of claims 1 to 7, wherein said vector is itself integrated into a plant pathogen.
9. Process according to claim 8, wherein: v said plant host cell is from Nicotiana benthamiana, v said plant pathogen is Agrobacterium tumefaciens, and v said transforming step is a transient transformation.
10. Process according to any one of claims 1 to 9, wherein said transforming step is performed in the presence of a phenolic compound, said phenolic compound being preferably chosen among: acetosyringone, coniferyl alcohol, cinnamic acid, coumarin and vanillin.
11. Transformed plant host cell comprising a vector comprising a nucleotide sequence chosen among: v SEQ ID N°1, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, a fragment of at least 150 nucleotides of SEQ ID N°1, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, and
26 LU501034 v SEQ ID N°4, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, a fragment of at least 150 nucleotides of SEQ ID N°4, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4.
12. Transformed plant host cell according to claim 11, wherein said plant host cell is a N. benthamiana cell comprising A. tumefaciens, wherein said A. tumefaciens comprising said nucleotide sequence coding for a protein exhibiting a laccase enzymatic activity.
13. Use of a nucleotide sequence chosen among v SEQ ID N°1, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, a fragment of at least 150 nucleotides of SEQ ID N°1, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°1, and v SEQ ID N°4, a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, a fragment of at least 150 nucleotides of SEQ ID N°4, a fragment of at least 150 nucleotides of a nucleotide sequence exhibiting at least 80% identity with SEQ ID N°4, for the production of at least one nornicotine acyl-derivative in a plant host cell.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU501034A LU501034B1 (en) | 2021-12-17 | 2021-12-17 | Production of nornicotine acyl-derivatives in a plant host |
| PCT/EP2022/086017 WO2023111120A1 (en) | 2021-12-17 | 2022-12-15 | Production of nornicotine acyl-derivatives in a plant host |
| EP22839238.7A EP4448732A1 (en) | 2021-12-17 | 2022-12-15 | Production of nornicotine acyl-derivatives in a plant host |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU501034A LU501034B1 (en) | 2021-12-17 | 2021-12-17 | Production of nornicotine acyl-derivatives in a plant host |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU501034B1 true LU501034B1 (en) | 2023-06-19 |
Family
ID=79686819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU501034A LU501034B1 (en) | 2021-12-17 | 2021-12-17 | Production of nornicotine acyl-derivatives in a plant host |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4448732A1 (en) |
| LU (1) | LU501034B1 (en) |
| WO (1) | WO2023111120A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63126875A (en) | 1986-11-14 | 1988-05-30 | Japan Tobacco Inc | Nornicotine derivative, production thereof and germination inhibitor containing said compound as active ingredient |
| US20140080794A1 (en) | 2008-09-29 | 2014-03-20 | Vivus, Inc. | Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders |
| WO2016196878A1 (en) * | 2015-06-04 | 2016-12-08 | Altria Client Services Llc | Acyl nornicotines reduce sensory irritation in tobacco and nicotine products |
| US20200360734A1 (en) | 2011-01-31 | 2020-11-19 | Lucolas-M.D. Ltd. | Cosmetic use |
-
2021
- 2021-12-17 LU LU501034A patent/LU501034B1/en active IP Right Grant
-
2022
- 2022-12-15 WO PCT/EP2022/086017 patent/WO2023111120A1/en not_active Ceased
- 2022-12-15 EP EP22839238.7A patent/EP4448732A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63126875A (en) | 1986-11-14 | 1988-05-30 | Japan Tobacco Inc | Nornicotine derivative, production thereof and germination inhibitor containing said compound as active ingredient |
| US20140080794A1 (en) | 2008-09-29 | 2014-03-20 | Vivus, Inc. | Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders |
| US20200360734A1 (en) | 2011-01-31 | 2020-11-19 | Lucolas-M.D. Ltd. | Cosmetic use |
| WO2016196878A1 (en) * | 2015-06-04 | 2016-12-08 | Altria Client Services Llc | Acyl nornicotines reduce sensory irritation in tobacco and nicotine products |
Non-Patent Citations (12)
| Title |
|---|
| EARLEY ET AL.: "Gateway compatible vectors for plant functional genomics and proteomics", PLANT. J., vol. Feb, no. 45, 2006, pages 616 - 29 |
| KADOHAMA ET AL.: "Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase", CANCER LETT., vol. 75, 1993, pages 175 - 182, XP023162726, DOI: 10.1016/0304-3835(93)90060-M |
| LAUE G. ET AL.: "Fast track to the trichome: induction of N-acyl nornicotines precedes nicotine induction in Nicotiana repanda", PLANTA, vol. 210, 2000, pages 510 - 514 |
| MATELJAK ET AL.: "Increasing redox potential, redox mediator activity and stability in a fungal laccase by computer-guided mutagenesis and directed evolution", ACS CATALYSIS, vol. 9, 2019, pages 4561 - 72 |
| MATELJAK ET AL.: "Increasing redox potential, redox mediator activity, and stability in a fungal laccase by computer-guided mutagenesis and directed evolution", ACS CATALYSIS, vol. 9, pages 4561 - 4572 |
| MATSUZAKI T. ET AL.: "Germination and Growth Inhibition of Acylnornicotines from Section Repandae of the Genus Nicotiana and Synthetic Acylnornicotines", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 52, 1988, pages 1899 - 1903, XP055113319, DOI: 10.1271/bbb1961.52.1899 |
| NEEDLEMANWUNSCH: "A general method applicable to the search for similarities in the amino acid sequences of two proteins", J. MOL. BIOL., vol. 48, no. 3, pages 443 - 53 |
| OSAWA, Y. ET AL.: "Aromatase inhibitors in cigarette smoke, tobacco leaves and other plants", J. ENZYME INHIB., vol. 4, 1990, pages 187 - 200 |
| OUTCHKOUROV ET AL.: "Control of anthocyanin and non-flavonoid compounds by anthocyanin-regulating MYB and bHLH transcription factors in Nicotiana benthamiana leaves", FRONT. PLANT SCI., 2014, pages 5 |
| OUTCHKOUROV NIKOLAY S. ET AL: "Control of anthocyanin and non-flavonoid compounds by anthocyanin-regulating MYB and bHLH transcription factors in Nicotiana benthamiana leaves", FRONTIERS IN PLANT SCIENCE, vol. 5, 8 October 2014 (2014-10-08), XP055946719, DOI: 10.3389/fpls.2014.00519 * |
| WANG, C.WILSON, L. F, METHODS AND COMPOSITIONS FOR THE TREATMENT OF ESTROGEN-DEPENDENT HYPERPROLIFERATIVE UTERINE DISORDERS, 2014 |
| ZENKNER FERNANDA FLEIG ET AL: "Nicotine Biosynthesis in Nicotiana: A Metabolic Overview", TOBACCO SCIENCE, 1 April 2019 (2019-04-01), pages 1 - 9, XP055888894, Retrieved from the Internet <URL:https://meridian.allenpress.com/tobacco-science/article/56/1/1/446420> [retrieved on 20220208], DOI: 10.3381/18-063 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023111120A1 (en) | 2023-06-22 |
| EP4448732A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mehta et al. | A developmental gradient reveals biosynthetic pathways to eukaryotic toxins in monocot geophytes | |
| JP2017514480A (en) | A novel ginsenoside glycosyl transfer method using glycosyltransferase from ginseng | |
| EP0293357A1 (en) | Expression of human proapolipoprotein A-1 | |
| Cubells-Baeza et al. | Identification of the ligand of Pru p 3, a peach LTP | |
| CN108048415B (en) | Two myricetin flavonol synthetase MrFLSs proteins and application of coding genes thereof | |
| US20220275385A1 (en) | Anthocyanin biosynthesis in carrot plants | |
| CN106282202B (en) | Artemisia apiacea HD-ZIP IV transcription factor coding sequence and application | |
| Yang et al. | Establishment of recombinant Catharanthus roseus stem cells stably overexpressing ORCA4 for terpenoid indole alkaloids biosynthesis | |
| LU501034B1 (en) | Production of nornicotine acyl-derivatives in a plant host | |
| EP4457336A2 (en) | Genetically modified organisms for producing psychotropic alkaloids | |
| CN113826502B (en) | A method for increasing the flavonoid content in Camellia oleifera seeds | |
| Zhu et al. | Divergent fatty acid desaturase 2 is essential for falcarindiol biosynthesis in carrot | |
| CN109486849B (en) | CPR and CYP9A12 double gene co-expression recombinant vector and preparation method and application thereof | |
| CN107345232B (en) | Glucosyltransferase genes involved in post-transformation modifications in biosynthesis | |
| WO2024114876A1 (en) | Methods for producing celastrol | |
| CN120718915B (en) | A camphor MYB transcription factor gene and its application | |
| CN114214339A (en) | A kind of hemp THCSAS2 gene and its encoded product terpene phenolic acid oxidative cyclase and its application | |
| Sun et al. | The effects of protopine 6-hydroxylase (P6H) overexpression on benzylisoquinoline alkaloids in Macleaya cordata | |
| Azi et al. | Sustainable bioproduction of triterpenoid sapogenins and meroterpenoids in a metabolically engineered medicinal mushroom | |
| BE1032469B1 (en) | LmMYB111 GENE AND APPLICATION TO THE REGULATION OF CHLOROGENIC ACID CONTENT IN LONICERA MACRANTHOIDES | |
| CN116732060B (en) | CYP716C oxidase gene in camptotheca acuminata, carrier, microsomal protein and application thereof | |
| CN116813733B (en) | Lycium barbarum ERF transcription factor and application thereof | |
| KR20190050296A (en) | Method for producing transgenic plant with increased content of 20-hydroxyecdysone using genes from insect and the plant thereof | |
| CN105132389B (en) | The methyl glutaryl coenzyme A reductase of 3 hydroxyl 3 and its encoding gene and application | |
| CN119082094B (en) | Oxidation squalene cyclase MtBUTS, coding gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20230619 |